Industry giants like Takeda Pharmaceuticals, Pfizer, Novartis, and Bayer are revolutionizing treatment landscapes, paving the way for enhanced patien ...

Reported recurrence rates of lentigo maligna treated with Mohs micrographic surgery have ranged from 0.5 to 30.0% in the literature.

A phase 1 study of a personalized cancer vaccine demonstrated antitumor immunity in all treated patients with resected renal ...

Researchers report that all nine patients in a clinical trial being treated for stage III or IV clear cell renal cell carcinoma (a form of kidney cancer), generated a successful anti-cancer immune ...

Researchers have published findings from the phase 2 LITESPARK-003 study of patients with previously untreated advanced clear ...

An experimental vaccine for kidney cancer is off to a promising start. In data from a Phase I trial released this week, the ...

Ac-satoreotide is a first-in-class Actinium-labelled somatostatin receptor 2 antagonist targeting extensive-stage Small Cell Lung Cancer or Merkel Cell Carcinoma Orphan Drug Designation follows ...

During a live event, Kathryn E. Beckermann, MD, PhD, discussed the treatment of RCC with insights from a recent trial on ...

Saquon Barkley can win his first Super Bowl with Eagles, not Giants. That won't stop all Big Blue fans from rooting for him, especially not this one.

Nearly 60,000 people are diagnosed with oral cancer in the U.S. every year, according to the American Cancer Society, and the rate of new cases continues to rise.

All patients involved in the phase 1 trial of a personalized cancer vaccine for high-risk stage III/IV kidney cancer showed a successful anticancer immune response.

In a small clinical trial of nine patients with stage III and IV kidney cancer, a personalized anti-tumor vaccine generated ...